According to the latest research report of Jefferies, the following five biotech companies are likely to become acquisition targets of bio- or pharmaceutical giants.
1. Bluebird creature
Bluebird Bio (BLUE) is a biotechnology company dedicated to gene therapy. On December 14, 2016, Bluebird announced that it will use the Northstar-2 for the first patient and the LentiGlobin Phase III clinical trial for patients with blood transfusion-dependent beta-thalassemia (TDT).
Wall Street set its target price at $84.43. Bluebird stock is currently trading at $68.95.
2. Incyte
Incyte (INCY), a pharmaceutical company dedicated to oncology treatment, ranks high on the list of most investors. Recently, investors hope and urge Gilead Science Corporation (GILD) to acquire Incyte. The acquisition of Incyte will boost sales and patent fees for Jakafi's anti-cancer drugs. Last year the drug generated about $1 billion in revenue and is expected to grow further in the future. At the same time, baricitinib is expected to receive treatment for rheumatoid arthritis in the first quarter of this year, and its patent fees are considerable. In addition, the company has a strong product line.
Wall Street set its target price at $109.58. The Incyte stock is currently trading at $107.17.
3. Medicines Company
The US biopharmaceutical companies Medicines Company (MDCO) and Alnylam Pharmaceuticals (ALNY) announced on November 15, 2016 that the results of the Phase II study of inclisiran in the treatment of hypercholesterolemia in 2016 were optimistic.
The company's cardiovascular, infectious disease and surgical care products are available. In addition to inclisiran, the company also has an anesthetic ABP-700 in the development phase, as well as Carbavance for the treatment of bacterial infections.
The Medicines Company stock is currently trading at $36.02.
Auto Hematology Analyzer,Clinical Hematology Analyzer,Blood Analyzer Hematology,Hematology Analyzer
Guangdong Widinlsa International Co.Ltd , https://www.gdwidinlsa.com